Ulrika Rönningås

Satisfaction with treatment decision-making and long-term experiences of life-prolonging treatments for metastatic castration-resistant prostate cancer

BACKGROUND: Treatments in the phase of metastatic castration-resistant prostate cancer (mCRPC) aim to prolong survival and reduce the symptom burden. The fast development of life-prolonging therapies makes treatment decision-making (TDM) complex, weighting survival against possib...